相关实验视频

Updated: Feb 27, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

在患有复发性/逆转性多发性骨髓瘤和功能障碍的患者中进行BCMA指导的CAR T细胞疗法

Alma Habib^1,2,3, Nausheen Ahmed^1,2, Abdullah Mohammad Khan^2,3

¹Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA.

Current oncology (Toronto, Ont.)

|February 26, 2026

概括

BCMA CAR-T疗法在复发性/耐药性多发性骨髓瘤患者的功能障碍中表现出类似的疗效. 然而,这些患者的神经毒性和感染率较高,需要仔细监测.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
血液学血液学血液学

背景情况:

以BCMA指导的CAR T细胞疗法对复发性和耐火性多发性髓瘤 (RRMM) 显示出前景.
患者适合性对于那些有低于最佳器官功能,特别是功能障碍 (RI) 的人来说是一个挑战.

研究的目的:

评估BCMA CAR-T疗法的安全性和有效性,用于RRMM患有功能障碍 (RI) 的患者.

主要方法:

在223名RRMM患者的多中心回顾性研究中,他们接受了idecabtagene vicleucel或ciltacabtagene autoleucel治疗.
基线NI (CrCL < 45 mL/min) 和正常功能 (nRF) 队列之间的患者结局的比较.

主要成果:

在RI和nRF组之间,在1,3个月和6个月的可比反应率.
无进展生存期 (PFS) 在RI组 (21.9个月) 与nRF (15个月) 较长.
患有RI的患者患有更高的免疫效应细胞相关神经毒性综合征 (ICANS) 和感染率.

结论:

在RRMM患者中,BCMA CAR-T疗法在基线功能障碍患者中表现出可比的疗效.
在RI患者中神经毒性和感染率的增加需要警的监测和管理.

关键词:

这就是为什么BCMABCMABCMA.仿制性抗原受体T细胞疗法多发性骨髓瘤是多发性骨髓瘤的一种.造成功能衰竭.

更多相关视频

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...